Researchers find important gene for lupus

Researchers at the University of Minnesota have identified, for the first time, a gene variation associated with systemic lupus erythematosus (SLE), a potentially fatal disease which causes the body's defence system to attack itself.

The gene variation, known as PTPN22, is found in approximately 16 percent (or one in six) of healthy Caucasians in the United States. However, nearly one in four (or 23 percent) lupus patients carry this variant, which has also now been associated with risk for type 1 diabetes and rheumatoid arthritis. The study is published in the September edition of the American Journal of Human Genetics.

"This appears to be a very important gene for lupus," said Timothy W. Behrens, M.D., professor of medicine, Medical School, and principal investigator, "and this is the first time we have identified a variant that predisposes to many different autoimmune diseases. We hope that this discovery will lead to the identification of other genes associated with lupus and other immune disorders." Behrens believes that dozens of genes may be responsible for lupus and that discovering the combination of these genes will be important to developing better diagnosis and treatment of the disease.

In SLE, a person's immune system begins attacking its own tissues. Organs commonly targeted in SLE include the skin, kidneys, joints, lungs, and the central nervous system. The severity of disease and the response to therapy vary widely between patients, said Behrens, and this leads to significant challenges in the diagnosis and management of lupus. "If we know which genes predispose a person to lupus, we may be able to diagnose and treat the disease earlier," he said. "In addition to discovering which combination of genes lead to lupus and other immune diseases, we also hope this information will help us identify new drugs and therapies."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis